White House looks for path to provide experimental Ebola drugs to infected patients

Drugmakers who sell unapproved drugs are generally setting themselves up for big penalties from federal authorities. The Obama administration, under mounting pressure, intends to craft a policy for using experimental drugs to treat the Ebola virus, Reuters reports. The White House Friday said it is setting up a working group to consider the use of drugs on the hundreds patients in Africa infected by the deadly virus, which has killed nearly 1,000 so far. The FDA already allowed an experimental drug from California-based Mapp Biopharmaceutical to be used to treat two U.S. aid workers who became infected. But any accelerated use of the drugs poses potential threats to patients and the drugmakers, so a policy and pathway to use will have to be designed carefully. Story | More

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.